ALNY Q4 2025 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.1B+84.9% YoY

Gross Profit

$829M75.6% margin

Operating Income

$132M12.0% margin

Net Income

$186M17.0% margin

EPS (Diluted)

$1.37

QoQ Revenue Growth

-12.2%

Cash Flow

Operating Cash Flow

$164M

Free Cash Flow

$140M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$5.0B

Total Liabilities

$4.2B

Stockholders' Equity

$789M

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$593M	+84.9%
Gross Profit	$829M	$490M	+69.1%
Operating Income	$132M	-$105M	+225.3%
Net Income	$186M	-$84M	+322.6%

Revenue Segments

GIVLAARI

$161M69%

ONPATTRO

$71M31%

Geographic Segments

UNITED STATES

$1.2B78%

Europe

$233M15%

Non-US Or Europe

$107M7%